Retatrutide, is being studied as a triple hormone receptor agonist. It is designed to activate three metabolic hormone pathways: GIP, GLP-1, and glucagon receptors. Because of this triple-action profile, retatrutide is being investigated in research related to body-weight regulation, appetite signaling, glucose metabolism, energy expenditure, liver-fat reduction, and broader cardiometabolic health markers.
Potential Human Benefits Being Investigated
- Body-weight regulation research
- Appetite and satiety signaling
- Food-intake and craving-related pathways
- GLP-1 receptor pathway research
- GIP receptor pathway research
- Glucagon receptor pathway research
- Energy-expenditure and metabolic-rate research
- Fat-mass reduction research
